Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients

1

Review clinical trials related to Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

Breakthrough chemotherapy-induced vomiting (CIV) is defined as CIV occurring after adequate antiemetic prophylaxis. Olanzapine is recommended for the treatment of breakthrough CIV in children, without adequate evidence. We conducted an open-label, single-center, phase 3 randomized controlled trial comparing the safety and efficacy of olanzapine and metoclopramide for treating breakthrough CIV.

Participants needed: 100
Trial details
Phase: Phase 3Age: 5-18Biological sex: AllType: InterventionalSponsor: Shanghai Children's Medical CenterUpdated: Jun 25, 2025Locations: 1
Eligibility criteria

Children with history of allergy to olanzapine or metoclopramide; patient with r...